Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FGH10019
Cat. No.:
OB0225LY-0016
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
FGH10019 is a high-quality inhibitor of sterol regulatory element-binding protein (SREBP), presenting significant implications for drug discovery.
Synonym:
FGH-10019; 1046045-61-7; N-(4-(2-(2-Propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide; N-[4-[2-(2-Propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]methanesulfonamide; N-{4-[2-(2-Propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl}methanesulfonamide
CAS No.:
1046045-61-7
Compound CID:
25012898
Formula:
C18H19N3O2S2
Formula Weight:
373.49
Specification
Relative Density:
1.307 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FGH10019 can be used for high-throughput screening and metabolic disorder studies.
Library Information
Targets:
NPC1L1; Fatty acid synthesis
Receptors:
Fatty acid synthase; SREBPs
Pathways:
Membrane transporter/Ion channel; Metabolism
Plate Number:
AOCL-1
Plate Location:
b7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
38 mg/mL; 101.74 mM
